
Five years ago, insulin prices were under such high pressure that Novo Nordisk had to downgrade its guidance multiple times, resulting in grave share price declines. The financial analyst Jefferies predicts Novo's growth engine with GLP-1 medication may encounter a similar type of pressure after 2023-24, when the patent for Novo Nordisk's first big seller in the GLP-1 series, Victoza, expires, according to Danish business daily Børsen.
"Our biggest worry is whether the price pressure, when Victoza generics are made accessible, will be transferred to the GLP-1 class or limited, since this is a daily treatment, and alleviated by the better-working Ozempic, or the more comfortable treatment Rybelsus," writes Jefferies Pharma & Biotech Research Analyst Peter Welford in a comment.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app